Search Within

Michael Morris

  1. "European Journal of Cancer"
Formats
  1. Meeting Abstract (4)
  2. Journal Article (3)
Groups
  1. Department of Medicine (7)
  2. Genitourinary Oncology Service (7)
  3. Solid Tumor Oncology Division (7)
  4. GSK Faculty (2)
  5. Hematologic Malignancies, Division of (2)
  6. Sloan Kettering Institute Faculty (2)

More Groups

People
  1. Howard Scher (2)
  2. Anuradha Gopalan (1)
  3. Carlos Cordon-Cardo (1)
  4. Charles Sawyers (1)
  5. Dana Pe'er (1)
  6. Dana Rathkopf (1)

More People

Years
  1. 2023 (1)
  2. 2022 (1)
  3. 2019 (1)
  4. 2018 (1)
  5. 2015 (1)
  6. 2013 (1)

More Years

Publications
  1. European Journal of Cancer (7)
Publishers
  1. Elsevier Inc. (7)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
    Journal Article

    Gillessen, S.; Bossi, A.; Davis, I. D.; de Bono, J.; Fizazi, K.; James, N. D.; Mottet, N.; Shore, N.; Small, E.; Smith, M.; more...
    European Journal of Cancer (2023)

    Fulltext@MSK | Save
  • Lineage plasticity in prostate cancer depends on FGFR and JAK/STAT inflammatory signaling
    Meeting Abstract

    Chan, J.; Zaidi, S.; Love, J.; Zhao, J.; Setty, M.; Wadosky, K.; Gopalan, A.; Choo, Z. N.; Persad, S.; Chaudhary, O.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: A phase 1 dose escalation/randomised phase 2a trial
    Journal Article

    Morris, M. J.; Loriot, Y.; Sweeney, C. J.; Fizazi, K.; Ryan, C. J.; Shevrin, D. H.; Antonarakis, E. S.; Pandit-Taskar, N.; Deandreis, D.; Jacene, H. A.; more...
    European Journal of Cancer (2019)

    Fulltext@MSK | Save
  • Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
    Journal Article

    Choueiri, T. K.; Hessel, C.; Halabi, S.; Sanford, B.; Michaelson, M. D.; Hahn, O.; Walsh, M.; Olencki, T.; Picus, J.; Small, E. J.; more...
    European Journal of Cancer (2018)

    Fulltext@MSK | Save
  • Baseline characteristics, number of radium-223 (Ra-223) injections, and overall survival (OS) in US Expanded Access Program (EAP) and ALSYMPCA
    Meeting Abstract

    Sartor, O.; Coleman, R. E.; Morris, M. J.; Nilsson, S.; Shore, N.; Sweeney, C.; Vogelzang, N. J.; Petrenciuc, O.; Gratt, J.; Parker, C.
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • A validated prognostic model for predicting overall survival in patients with metastatic chemotherapy naive castrate-resistant prostate cancer
    Meeting Abstract

    Halabi, S.; Lin, C. Y.; Kelly, W. K.; Fizazi, K.; Moul, J. W.; Kaplan, E.; Morris, M. J.; Small, E. J.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • BCL-2 antisense (G3139) plus docetaxel for treatment of progressive androgen-independent prostate cancer
    Meeting Abstract

    Morris, M. J.; Tong, W. P.; Cordon-Cardo, C.; Drobnjak, M.; Kelly, W. K.; Slovin, S. F.; Rosen, N.; Scher, H. I.
    European Journal of Cancer (2001)

    Fulltext@MSK | Save